349 related articles for article (PubMed ID: 2144364)
1. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.
Raycroft L; Wu HY; Lozano G
Science; 1990 Aug; 249(4972):1049-51. PubMed ID: 2144364
[TBL] [Abstract][Full Text] [Related]
2. Presence of a potent transcription activating sequence in the p53 protein.
Fields S; Jang SK
Science; 1990 Aug; 249(4972):1046-9. PubMed ID: 2144363
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of the cellular p53 gene is a common feature of Friend virus-induced erythroleukemia: relationship of inactivation to dominant transforming alleles.
Munroe DG; Peacock JW; Benchimol S
Mol Cell Biol; 1990 Jul; 10(7):3307-13. PubMed ID: 1694008
[TBL] [Abstract][Full Text] [Related]
4. Analysis of p53 mutants for transcriptional activity.
Raycroft L; Schmidt JR; Yoas K; Hao MM; Lozano G
Mol Cell Biol; 1991 Dec; 11(12):6067-74. PubMed ID: 1944276
[TBL] [Abstract][Full Text] [Related]
5. Wild-type p53 can inhibit oncogene-mediated focus formation.
Eliyahu D; Michalovitz D; Eliyahu S; Pinhasi-Kimhi O; Oren M
Proc Natl Acad Sci U S A; 1989 Nov; 86(22):8763-7. PubMed ID: 2530586
[TBL] [Abstract][Full Text] [Related]
6. The product of the c-ets-1 proto-oncogene and the related Ets2 protein act as transcriptional activators of the long terminal repeat of human T cell leukemia virus HTLV-1.
Bosselut R; Duvall JF; Gégonne A; Bailly M; Hémar A; Brady J; Ghysdael J
EMBO J; 1990 Oct; 9(10):3137-44. PubMed ID: 2209540
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of a p53 gene mutation in a human osteosarcoma cell line.
Romano JW; Ehrhart JC; Duthu A; Kim CM; Appella E; May P
Oncogene; 1989 Dec; 4(12):1483-8. PubMed ID: 2531855
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional and post-transcriptional regulation of c-myc, c-myb, and p53 during proliferation and differentiation of murine erythroleukemia cells treated with DFMO and DMSO.
Klinken SP; Holmes KL; Morse HC; Thorgeirsson SS
Exp Cell Res; 1988 Oct; 178(2):185-98. PubMed ID: 2458948
[TBL] [Abstract][Full Text] [Related]
9. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene.
Chen J; Lin J; Levine AJ
Mol Med; 1995 Jan; 1(2):142-52. PubMed ID: 8529093
[TBL] [Abstract][Full Text] [Related]
10. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation.
Hinds P; Finlay C; Levine AJ
J Virol; 1989 Feb; 63(2):739-46. PubMed ID: 2642977
[TBL] [Abstract][Full Text] [Related]
11. Nuclear and nucleolar targeting sequences of c-erb-A, c-myb, N-myc, p53, HSP70, and HIV tat proteins.
Dang CV; Lee WM
J Biol Chem; 1989 Oct; 264(30):18019-23. PubMed ID: 2553699
[TBL] [Abstract][Full Text] [Related]
12. p53: oncogene or anti-oncogene?
Lane DP; Benchimol S
Genes Dev; 1990 Jan; 4(1):1-8. PubMed ID: 2137806
[No Abstract] [Full Text] [Related]
13. The p53 tumor suppressor gene and gene product.
Levine AJ
Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions.
Blagosklonny MV; Giannakakou P; Romanova LY; Ryan KM; Vousden KH; Fojo T
Carcinogenesis; 2001 Jun; 22(6):861-7. PubMed ID: 11375890
[TBL] [Abstract][Full Text] [Related]
15. Mutation of the serine 312 phosphorylation site does not alter the ability of mouse p53 to inhibit simian virus 40 DNA replication in vivo.
Meek DW; Eckhart W
J Virol; 1990 Apr; 64(4):1734-44. PubMed ID: 2157055
[TBL] [Abstract][Full Text] [Related]
16. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.
Finlay CA
Mol Cell Biol; 1993 Jan; 13(1):301-6. PubMed ID: 8417333
[TBL] [Abstract][Full Text] [Related]
17. Transactivation of the p53 oncogene by E1a gene products.
Braithwaite A; Nelson C; Skulimowski A; McGovern J; Pigott D; Jenkins J
Virology; 1990 Aug; 177(2):595-605. PubMed ID: 2142558
[TBL] [Abstract][Full Text] [Related]
18. Functional analysis of an isolated fos promoter element with AP-1 site homology reveals cell type-specific transcriptional properties.
Velcich A; Ziff EB
Mol Cell Biol; 1990 Dec; 10(12):6273-82. PubMed ID: 2147223
[TBL] [Abstract][Full Text] [Related]
19. Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53.
Hoppe-Seyler F; Butz K
J Virol; 1993 Jun; 67(6):3111-7. PubMed ID: 8388491
[TBL] [Abstract][Full Text] [Related]
20. A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP.
Zinszner H; Albalat R; Ron D
Genes Dev; 1994 Nov; 8(21):2513-26. PubMed ID: 7958914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
